Literature DB >> 19945634

Quality of life measurements in epidermolysis bullosa: tools for clinical research and patient care.

John W Frew1, Dédée F Murrell.   

Abstract

Quality of life (QOL) evaluation in epidermolysis bullosa (EB) has important applications in clinical management, patient advocacy, clinical research, and the development of new treatments. Several new quantitative and qualitative QOL measurement tools were developed recently, providing insight into the impact EB has on individuals and their family members. Selection of the most appropriate QOL tool for patients who have EB depends on not only the type of information required but also the general or specific cohort being examined. EB-specific quantitative tools possess the highest level of content validity and statistical accuracy. However, generic dermatologic tools may also be appropriate in some circumstances. Overall, QOL evaluation in EB is still a developing area of research that may help improve patient management and assess emerging treatment modalities for their efficacy in improving the QOL of patients with EB.

Entities:  

Mesh:

Year:  2010        PMID: 19945634     DOI: 10.1016/j.det.2009.10.019

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  9 in total

1.  Understanding the outcomes of a home nursing programme for patients with epidermolysis bullosa: an Australian perspective.

Authors:  Louise J Stevens; Sue McKenna; Jennifer Marty; Allison J Cowin; Zlatko Kopecki
Journal:  Int Wound J       Date:  2014-12-03       Impact factor: 3.315

Review 2.  Psychosocial impact of inherited and autoimmune blistering diseases.

Authors:  Swaranjali V Jain; Dedee F Murrell
Journal:  Int J Womens Dermatol       Date:  2018-01-08

3.  The quality of life in epidermolysis bullosa (EB-QoL) questionnaire: Translation, cultural adaptation, and validation into the Farsi language.

Authors:  Atoosa Yazdanshenas; Ezatollah Naderi; Hamideh Moravvej; Kazem Heidari; Masoomeh Faghankhani; Hassan Vahidnezhad; Nikoo Mozafari
Journal:  Int J Womens Dermatol       Date:  2020-06-03

4.  Autoimmune Bullous Disease Quality of Life (ABQoL) questionnaire: Validation of the translated Persian version in pemphigus vulgaris.

Authors:  Amir Teimourpour; Kowsar Hedayat; Fereshteh Salarvand; Narges Ghandi; Maryam Ghiasi; Hamidreza Mahmoudi; Kamran Balighi; Roja Toosi; Farnam Mohebi; Ali Nili; Maryam Daneshpazhooh; Dedee F Murrell; Cheyda Chams-Davatchi
Journal:  Int J Womens Dermatol       Date:  2020-03-26

5.  Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe.

Authors:  Aris Angelis; Panos Kanavos; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; Valentin Brodszky; Johann Matthias Graf von der Schulenburg; Karine Chevreul; Ulf Persson; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-23

Review 6.  Psychosocial recommendations for the care of children and adults with epidermolysis bullosa and their family: evidence based guidelines.

Authors:  K Martin; S Geuens; J K Asche; R Bodan; F Browne; A Downe; N García García; G Jaega; B Kennedy; P J Mauritz; F Pérez; K Soon; V Zmazek; K M Mayre-Chilton
Journal:  Orphanet J Rare Dis       Date:  2019-06-11       Impact factor: 4.123

7.  Assessing the quality of life in the families of patients with epidermolysis bullosa: The mothers as main caregivers.

Authors:  Fatemeh Chogani; Mohammad Mahdi Parvizi; Dedee F Murrell; Farhad Handjani
Journal:  Int J Womens Dermatol       Date:  2021-08-26

8.  A Cross Sectional, Observational Survey to Assess Levels and Predictors of Psychological Wellbeing in Adults with Epidermolysis Bullosa.

Authors:  Emma Dures; Nichola Rumsey; Marianne Morris; Kate Gleeson
Journal:  Health Psychol Res       Date:  2013-01-23

9.  Quality of Life and Economic Burden in Recessive Dystrophic Epidermolysis Bullosa.

Authors:  In Kyung Jeon; Hye Rang On; Soo-Chan Kim
Journal:  Ann Dermatol       Date:  2016-01-28       Impact factor: 1.444

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.